Abstract
Background: Over the past decades, the global prevalence of obesity has tripled, with the Kingdom of Saudi Arabia experiencing a notably higher rate of increase. While lifestyle modifications remain the first line of treatment, pharmacological interventions are often employed when dietary and exercise interventions prove insufficient. However, safety concerns, misuse, and limited knowledge about weight management medications (WMMs) pose serious challenges.
Objectives: The objectives of this study were to determine the level of knowledge and examine attitudes towards WMMs among the general population, and to explore the factors associated with these knowledge levels and attitude patterns.
Methods: A cross-sectional study was conducted among adults from the general population in Saudi Arabia from January 2023 to May 2023. Participants completed a validated, self-administered electronic questionnaire in Arabic language. The questionnaire captured sociodemographic, lifestyle and health data, knowledge about WMMs, and attitudes toward them. The outcome measures included knowledge and attitudes scores. Factors associated with knowledge and attitudes were analyzed using chi-square tests. Statistical significance was determined at a p-value of <0.05.
Results: Around 716 respondents were included in the final analysis. Most of the participants acknowledged diet 565 (78.9%) and exercise 621 (86.7%) as effective strategies to lose weight. Only 222 (31.0%) participants recognized pharmaceutical medications as a weight management strategy. Knowledge about specific weight loss medications varied, with the highest recognition for semaglutide (Ozempic®, Novo Nordisk, Bagsværd, Denmark) 236 (33.0%) and liraglutide (Saxenda®, Novo Nordisk, Bagsværd, Denmark) 228 (31.8%), while the other WMMs were not commonly known between participants. Regarding attitudes, the majority disagreed with statements that WMMs are more effective than diet/exercise 413 (57.7%), are safe 405 (56.6%), and are more convenient to use 408 (57.0%). Notably, about three-quarters [534 (74.6%)] of participants agreed that these medications require specialist’s counseling. No correlation was observed between knowledge score and attitude score (Pearson's correlation coefficient r=0.03; p=0.330). Respondents' knowledge about WMMs was significantly influenced by age, monthly income, educational level, psychiatric history, and previous use of WMMs (p<0.05). Adequate knowledge was more prevalent among participants aged 26-35, earning more than 20K SAR monthly, postgraduates, those with a psychiatric history, and past users of WMMs. Attitudes toward WMMs, however, showed no significant association with sociodemographic or health-related factors (p>0.05). However, prior use of WMMs significantly correlated with attitudes (p=0.007), with past users demonstrating more favorable attitudes.
Conclusion: This study reveals a limited knowledge and cautious attitude regarding WMMs in the Saudi population, despite the high prevalence of obesity. With prior use of WMMs correlating with better knowledge and more favorable attitudes, these findings emphasize the need for targeted interventions to enhance public awareness and safe usage of these medications.
Keywords: obesity management, weight loss, weight management drugs, saudi arabia, obesity intervention, public health interventions, pharmacological interventions, knowledge and attitudes, obesity, weight management medications (wmms)
Introduction
Obesity has tripled over the past decades globally, with the Kingdom of Saudi Arabia (KSA) demonstrating a rate of increase that is higher than many other countries [1-2]. In 2002, the prevalence of obesity and overweight in Saudi Arabia was estimated at 37.8%, and it increased to 54.3% in 2018, representing approximately a 50% increase in the past two decades [3-4]. This is subsequent to the notable transition in Saudi's lifestyle from a traditional towards a more Western lifestyle [5]. Several recent studies have shown that the Saudi population shifted to a more sedentary lifestyle, with increased consumption of high-calorie food and drinks, while physical activity decreased [6-7]. Moreover, the COVID-19 pandemic changed the nutritional habits of Saudis. During the lockdown, 58.1% of Saudi participants in a study reported an increase in their food consumption, their fast food (47.1%), and sweets (48.5%) consumption, while 30.8% reported gaining weight throughout the lockdown [8].
Individuals with obesity already have an increased risk of developing the 21st century's most frequent non-communicable chronic diseases such as hypertension, cardiovascular disease, type 2 diabetes (T2D), and certain cancers [9]. Therefore, reducing the levels of obesity is considered a major public health goal in Saudi Arabia. The Ministry of Health considered the elaboration of evidence-based data to promote citizens’ health by targeting a number of chronic diseases and cardiovascular factors including obesity and overweight. In 2015, 12 guidelines have been established considering at first intention the lifestyle interventions and prioritizing individualized counseling interventions with supportive cognitive and behavioral interventions. On the other hand, due to a lack of solid evidence, no recommendations were emitted regarding specific types of diet over others [10]. Primary care physicians and dietitians play a key role in assisting individuals with creating effective dietary strategies to manage their obesity [8]. Nevertheless, previous research demonstrated low adherence to healthy diet guidelines among the Saudi population [11].
Pharmacological interventions are considered when diet and physical exercise are insufficient. According to Saudi guidelines 2022, pharmaceutical management of obesity that was recommended by a panel of experts includes the use of liraglutide and orlistat in obese and overweight adults [12]. Furthermore, bariatric surgery was approved for morbid obesity or type III obesity with comorbidities [10]. Metformin is commonly used off-label in Saudi Arabia as a weight-reducing agent. However, it is not US-FDA or SFDA-approved as a WMM.
However, tolerability and safety of anti-obesity medication remain an issue in long-term usage [13]. Indeed, during the last few years, due to substantial side effects, the majority of weight management medications (WMMs) that were approved and advertised were withdrawn [14]. Currently, the US FDA has approved orlistat, phentermine/topiramate, naltrexone/bupropion, and liraglutide as anti-obesity drugs, each with a specific mechanism of action [15]. Lorcaserin was approved by the US FDA in 2012 [16]; it suppresses appetite by stimulating 5-HT2C receptors on the pro-opiomelanocortin (POMC) neurons [17]. However, the US FDA announced the withdrawal of lorcaserin from the industry in February 2020, after a clinical trial that revealed a serious side effect of the drug: elevated risk of cancer [18].
Another alarming aspect of the issue that was observed in several countries is the increasing misuse of medications, specially WMMs, without medical indication or prescription [19-20]. Furthermore, the knowledge of community pharmacists, notably in Saudi Arabia, on the potential side effects of weight management products is inadequate [21]. Poor knowledge of community pharmacists impacts the public's awareness of the risks and adverse effects of drugs, thus influencing the public attitude and behavior toward these medications, especially considering the sources of medication that were reported to be family, friends, and other non-physicians [20, 22]. This highlights the safety and risks of misuse as a major public health concern, which emphasizes the need for data on public awareness and knowledge about the use and risks related to such drugs.
This study was conducted to assess knowledge and attitude toward WMMs among the public. We assessed the knowledge of the general population about the available WMMs on the market and explored their attitudes regarding the safe use of these pharmaceutical products for weight loss. Furthermore, we examined the associated sociodemographic, lifestyle, and clinical factors, and explored the correlation between knowledge levels and attitude patterns. By focusing on the general public, the research aims to identify gaps in awareness and perceptions, enabling targeted educational interventions to promote responsible usage. Such data are important in promoting the safe and effective use of these medications, guiding further research and public health interventions in this emerging area of health care.
Materials and methods
Design and setting
A cross-sectional study was conducted, and participants were recruited from all regions of Saudi Arabia, between January and June 2023. The study protocol was ethically reviewed and approved by the Standing Committee for Scientific Research of Jazan University (Reference#: REC-44/09/599).
Population
Male and female adults aged 18 years and older, from the general population of Saudi Arabia were included. Individuals who use WMMs for diabetes mellitus were excluded. Participants with thyroid dysfunction and end-stage organ failure were also excluded. Participants below 18 years old and who declined to participate were excluded from the final dataset.
Sampling
The sample size was calculated to detect an unknown percentage (p=0.50) of adequate knowledge about WMMs, with a 95% confidence interval and 80% statistical power. A total of 377 individuals are necessary to meet the targeted statistical power. This goal was increased to N=400 to compensate for incomplete data. A convenience sampling was used to recruit all the consenting participants.
Tools
The study utilized a comprehensive, structured, and self-administered electronic questionnaire, which was designed by the primary investigator and subsequently validated by a family medicine consultant, a clinical nutrition specialist, and an epidemiologist. The questionnaire was administered in the Arabic language; however, the English version was used for ethical approval and statistical analysis. This questionnaire was segmented into four parts. Part A explored socio-demographic data such as age, gender, marital status, income, educational level, and health insurance status. Part B captured health and lifestyle data, subdivided into general health status (including history of eating disorders, other comorbidities, smoking, drug abuse, weight, height, and perception of own body image), dietary habits (previous consultation with a dietitian for weight management, prior diet, and perception of own dietary habits), and physical activity level. Part C assessed the participants' knowledge of weight management strategies, specifically their understanding of various weight management methods and their awareness of six WMMs: metformin (Glucophage®, Merck KGaA, Darmstadt, Germany), semaglutide (Ozempic, Wegovy®, Rybelsus®, Novo Nordisk, Bagsværd, Denmark), liraglutide (Saxenda), orlistat (Xenical®, Cheplapharm, Greifswald, Germany), phentermine/topiramate ER (Qysmia®, Vivus, Campbell, CA), and naloxone/bupropion (Contrave®, Orexigen Therapeutics, Inc., La Jolla, CA). Part D assessed attitudes toward WMMs, gathering respondents' level of agreement on statements such as "WMMs are more effective than diet and exercise," "WMMs are safe and pose no significant health risks," and "Weight loss achieved by using WMMs is long-lasting." The items were classified into two categories: "permissive" indicating a favorable stance, and "restrictive" for an unfavorable outlook on the use of WMMs; the latter category was scored using a reverse scale.
Pilot study
The questionnaire underwent pilot testing among 20 random participants, to test the validity and clarity of the items. The pilot sample of participants was not included in the main study.
Study outcomes
The present study comprises two dependent variables:
1) Knowledge about WMMs, indicated by a knowledge score (range 0-12) calculated as the number of weight-loss strategies (out of 6) and medications (out of 6) that were correctly identified by the participants. Adequate knowledge was determined as a knowledge score ≥7 out of 12.
2) Similarly, an attitude score (8-24) was calculated as the sum of the items’ scores and was dichotomized into unfavorable (score 8-15) and favorable (≥16).
Statistical methods
Data were analyzed using IBM Statistical Package for the Social Sciences (SPSS) for Windows, Version 21.0 (IBM Corp., Armonk, NY). Descriptive statistics were used to present the patterns of answers to the different questionnaire items. Cronbach’s alpha was calculated to evaluate the internal consistency of the study scales. Factors associated with knowledge (adequate vs inadequate) and attitudes (favorable vs unfavorable) were analyzed using chi-square test. A p-value <0.05 was used for statistical significance.
Results
Sociodemographic data
The final analysis included 716 participants from all regions of Saudi Arabia regardless of nationality. It revealed that the majority were females 443 (61.9%), aged between 26 and 35 [261 (36.5%)], and of Saudi nationality 691 (96.5%). Most were married 384 (53.6%) and did not have children 402 (56.1%). Predominantly, participants were in the income bracket of less than 7K SAR 348 (48.6%), and their professional status was employed 338 (47.2%). The majority held a university degree 463 (64.7%) and did not have health insurance 494 (69.0%). Concerning residency, participants were approximately equally distributed among the center 207 (28.9%), east 187 (26.1%), and west 181 (25.3%) regions (Table 1).
Table 1. Sociodemographic data (N=716).
| Parameter | Level | Frequency | Percentage |
| Gender | Male | 273 | 38.1 |
| Female | 443 | 61.9 | |
| Age | 18-25 | 198 | 27.7 |
| 26-35 | 261 | 36.5 | |
| 36-45 | 158 | 22.1 | |
| 46-50 | 51 | 7.1 | |
| Above 50 | 48 | 6.7 | |
| Nationality | Saudi | 691 | 96.5 |
| Non-Saudi | 25 | 3.5 | |
| Marital status | Single | 302 | 42.2 |
| Married | 384 | 53.6 | |
| Divorced | 28 | 3.9 | |
| Widowed | 2 | 0.3 | |
| Number of children | None | 402 | 56.1 |
| One | 0 | 0.0 | |
| Two or more | 314 | 43.9 | |
| Monthly income | <7K SAR | 348 | 48.6 |
| 7K-15K SAR | 219 | 30.6 | |
| 15K-20K SAR | 96 | 13.4 | |
| >20K SAR | 53 | 7.4 | |
| Professional status | Housewife | 157 | 21.9 |
| Employed | 338 | 47.2 | |
| Businessman/self employed | 16 | 2.2 | |
| Student | 183 | 25.6 | |
| Retired | 22 | 3.1 | |
| Educational level | Primary or lower | 5 | 0.7 |
| Middle school | 14 | 2.0 | |
| Secondary school | 142 | 19.8 | |
| University | 463 | 64.7 | |
| Post-graduate | 92 | 12.8 | |
| Health insurance status | None | 494 | 69.0 |
| Through employer | 199 | 27.8 | |
| Purchased directly | 23 | 3.2 | |
| Residency region | North | 75 | 10.5 |
| South | 66 | 9.2 | |
| Center | 207 | 28.9 | |
| East | 187 | 26.1 | |
| West | 181 | 25.3 |
Health and lifestyle data
Analysis of health and lifestyle data for the 716 participants revealed that dyslipidemia 166 (23.2%) and eating disorders 124 (17.3%) were the most common chronic diseases among participants. The majority were non-smokers 586 (81.8%) and fell within the normal weight 281 (39.2%) or overweight 263 (36.7%) categories. About 280 (39.1%) had considered and succeeded in a weight-loss program, while 196 (27.4%) attempted but failed. Most participants never consulted a dietitian 496 (69.3%) or a coach 487 (68.0%). Slightly more than half had never or only once followed a diet to lose weight [266 (37.2%) and 148 (20.7%) respectively] and never or only once followed a workout program [303 (42.3%) and 153 (21.4%) respectively]. The majority were somewhat watchful of their eating habits 415 (58.0%). Participants predominantly had a low-activity job 282 (39.4%) and exercised almost never or one to two times per week [308 (43.0%) and 233 (32.5%) respectively]. Approximately 256 (35.8%) reported walking durations of less than 30 min (Table 2).
Table 2. Health and lifestyle data (N=716).
| Parameter | Level | Frequency | Percentage |
| Chronic diseases | Hypertension | 43 | 6.0 |
| Type 2 diabetes | 33 | 4.6 | |
| Thyroid dysfunction | 44 | 6.1 | |
| Dyslipidemia | 166 | 23.2 | |
| Eating disorder | 124 | 17.3 | |
| Asthma | 12 | 1.7 | |
| GIT (Ulcer, IBS…etc.) | 11 | 1.5 | |
| Psychiatric history | 48 | 6.7 | |
| Other chronic disease | 63 | 8.8 | |
| No. comorbidities | None | 398 | 55.6 |
| 1 | 179 | 25.0 | |
| 2 | 80 | 11.2 | |
| 3+ | 59 | 8.2 | |
| Smoking | None-smoker | 586 | 81.8 |
| Ex-smoker | 28 | 3.9 | |
| Current smoker | 102 | 14.2 | |
| Weight-range | Underweight | 54 | 7.5 |
| Normal weight | 281 | 39.2 | |
| Overweight | 263 | 36.7 | |
| Obese | 118 | 16.5 | |
| Weight loss consideration | Never | 143 | 20.0 |
| Yes, but never attempted | 97 | 13.5 | |
| Yes, but failed | 196 | 27.4 | |
| Yes, and succeeded | 280 | 39.1 | |
| Dietitian consult | Never | 496 | 69.3 |
| Only once | 128 | 17.9 | |
| More than once | 92 | 12.8 | |
| Diet to lose weight | Never | 266 | 37.2 |
| Only once | 148 | 20.7 | |
| More than once | 302 | 42.7 | |
| Eating habits | Not watchful | 264 | 36.9 |
| Somewhat watchful | 415 | 58.0 | |
| Very watchful | 37 | 5.2 | |
| Physical exercise rhythm | Almost never | 308 | 43.0 |
| 1-2 per week | 233 | 32.5 | |
| 3-4 per week | 132 | 18.4 | |
| 5 or more per week | 43 | 6.0 | |
| Walking duration | None | 182 | 25.4 |
| <30 min | 256 | 35.8 | |
| 30-60 min | 218 | 30.4 | |
| >1 h | 60 | 8.4 | |
| Job type | Sedentary | 255 | 35.6 |
| Low activity | 282 | 39.4 | |
| Moderate activity | 156 | 21.8 | |
| High activity | 23 | 3.2 | |
| Coach consult | Never | 487 | 68.0 |
| Only once | 135 | 18.9 | |
| More than once | 94 | 13.1 | |
| Workout program | Never | 303 | 42.3 |
| Only once | 153 | 21.4 | |
| More than once | 260 | 36.3 |
Knowledge about weight management strategies
The knowledge of participants about weight management strategies was limited. The majority acknowledged diet 565 (78.9%) and exercise 621 (86.7%) as effective strategies but had less consensus on the use of herbal products 148 (20.7%), pharmaceutical drugs 222 (31.0%), cognitive and behavioral therapy 333 (46.5%), and surgery 325 (45.4%). Knowledge about specific weight-loss medications varied, with the highest recognition for semaglutide (Ozempic, Wegovy®, Rybelsus®) 236 (33.0%) and liraglutide (Saxenda) 228 (31.8%), while naloxone/bupropion (Contrave®) and phentermine/topiramate ER (Qysmia®) had the least recognition [43 (6.0%) and 42 (5.9%) respectively]. Uncertainty was particularly high for phentermine/topiramate ER (Qysmia®), naloxone/bupropion (Contrave), and orlistat (Xenical®, Cheplapharm, Greifswald, Germany) with 422 (58.9%), 416 (58.1%), and 384 (53.6%) respectively answered "Not sure" if used for weight loss (Table 3).
Table 3. Knowledge about weight management strategies (N=716).
| Question | Item | No (%) | Yes (%) | Not sure (%) |
| Among the following items, which are strategies that can be used to lose weight? | Diet | 97 (13.5) | 565 (78.9) | 54 (7.5) |
| Exercise | 60 (8.4) | 621 (86.7) | 35 (4.9) | |
| Herbal products | 411 (57.4) | 148 (20.7) | 157 (21.9) | |
| Pharmaceutical drugs | 375 (52.4) | 222 (31.0) | 119 (16.6) | |
| Cognitive and behavioral therapy | 236 (33.0) | 333 (46.5) | 147 (20.5) | |
| Surgery | 330 (46.1) | 325 (45.4) | 61 (8.5) | |
| Among the following drugs, which can be used to lose weight? | Liraglutide (Saxenda®) | 184 (25.7) | 228 (31.8) | 304 (42.5) |
| Metformin (Glucophage®) | 252 (35.2) | 124 (17.3) | 340 (47.5) | |
| Orlistat (Xenical®) | 209 (29.2) | 123 (17.2) | 384 (53.6) | |
| Semaglutide (Ozempic®, Wegovy®, Rybelsus®) | 186 (26.0) | 236 (33.0) | 294 (41.1) | |
| Naloxone/bupropion (Contrava®) | 257 (35.9) | 43 (6.0) | 416 (58.1) | |
| Phentermine/topiramate ER (Qysmia®) | 252 (35.2) | 42 (5.9) | 422 (58.9) |
Attitudes toward WMMs
Participants demonstrated cautious attitudes toward WMMs. The majority disagreed with statements that WMMs are more effective than diet/exercise 413 (57.7%), are safe 405 (56.6%), and are more convenient to use 408 (57.0%), resulting in low favorability scores of 1.49, 1.48, and 1.60 respectively. Participants were split between disagree 166 (23.2%) and agree 165 (23.0%) on whether WMMs enable rapid results, with a favorability score of 2.00. Similarly, for the statement concerning the long-lasting effect of WMMs on weight loss, most answers were neutral 382 (53.4%) or disagreed 221 (30.9%), yielding a favorability score of 1.85. Restrictive attitudes also varied, with the majority agreeing that WMMs require specialist's counseling 534 (74.6%) and should be restricted to those who failed to lose weight with diet/exercise 303 (42.3%). Most participants agreed that WMMs should only be used by people with extreme obesity 367 (51.3%). Favorability scores were 1.34, 1.78, and 1.65 respectively for these statements (Table 4).
Table 4. Attitudes toward WMMs.
WMMs, weight management medications; SD, standard deviation
*Reverse-scoring item (favorability score takes into consideration the type of the attitude and expresses how favorable is the participant’s answer to WMMs in the given item).
| Attitude | Type | Disagree | Neutral | Agree | Favorability score (mean, SD: out of 3) |
| WMMs are more effective than diet/exercise | Permissive | 413 (57.7) | 252 (35.2) | 51 (7.1) | 1.49 (0.63) |
| WMMs should be restricted to those who failed to lose weight with diet/exercise | Restrictive * | 142 (19.8) | 271 (37.8) | 303 (42.3) | 1.78 (0.76) |
| WMMs are safe | Permissive | 405 (56.6) | 281 (39.2) | 30 (4.2) | 1.48 (0.58) |
| WMMs require a specialist’s counseling | Restrictive | 58 (8.1) | 124 (17.3) | 534 (74.6) | 1.34 (0.62) |
| WMMs are more convenient to use | Permissive | 408 (57.0) | 183 (25.6) | 125 (17.5) | 1.60 (0.77) |
| WMMs enable rapid results | Permissive | 166 (23.2) | 385 (53.8) | 165 (23.0) | 2.00 (0.68) |
| Weight loss with WMMs is long-lasting | Permissive | 221 (30.9) | 382 (53.4) | 113 (15.8) | 1.85 (0.67) |
| WMMs should only be for people with extreme obesity | Restrictive | 117 (16.3) | 232 (32.4) | 367 (51.3) | 1.65 (0.74) |
Reliability of the study scales
Reliability analysis showed the scale for knowledge about weight management strategies was highly reliable (Cronbach's alpha = 0.885) with a mean score of 4.20, standard deviation (SD) of 2.50, and range of 0-12. The attitudes toward WMMs scale exhibited modest reliability (Cronbach's alpha = 0.675) with a mean score of 13.18, SD of 2.30, and range of 8-21. Higher scores indicate better knowledge and more favorable attitudes (Table 5). Notably, no correlation was observed between knowledge score and attitude score (Pearson's correlation coefficient r = 0.03; p=0.330).
Table 5. Reliability analysis of the study scales.
Depending on the scale, higher scores indicate higher knowledge and more favorable attitudes.
| Scale | No. items | Cronbach’s alpha | Score statistics | ||
| Mean | SD | Range | |||
| Knowledge about weight management strategies | 12 | 0.885 | 4.20 | 2.50 | 0-12 |
| Attitudes toward WMMs | 8 | 0.675 | 13.18 | 2.30 | 8-21 |
Factors associated with knowledge about WMMs
Table 6 presents the factors associated with knowledge about weight management. Age was found to be a key influencer, as those between 26 and 35 years old were most likely to have adequate knowledge (p=0.010*). Monthly income also showed to be a significant factor, with respondents earning more than 20K SAR displaying the highest level of adequate knowledge (p<0.001*). Education was another significant factor, as postgraduates demonstrated the most extensive knowledge (p=0.020*). Remarkably, respondents with a psychiatric history showed considerably higher knowledge levels (p=0.005*), and those who had used WMMs in the past were significantly more likely to have adequate knowledge than those who had not (p<0.001*). These results highlighted the influence of socioeconomic factors, health conditions, and previous use on knowledge levels about WMMs.
Table 6. Factors associated with knowledge.
WMM, weight management medication; GIT, gastrointestinal tract; IBS, irritable bowel syndrome
| Factor | Level | Inadequate level | Adequate | p-Value | ||
| N | % | N | % | |||
| Gender | Male | 203 | 74.4 | 70 | 25.6 | |
| Female | 310 | 70.0 | 133 | 30.0 | 0.206 | |
| Age | 18-25 | 141 | 71.2 | 57 | 28.8 | |
| 26-35 | 169 | 64.8 | 92 | 35.2 | ||
| 36-45 | 124 | 78.5 | 34 | 21.5 | ||
| 46-50 | 42 | 82.4 | 9 | 17.6 | ||
| Above 50 | 37 | 77.1 | 11 | 22.9 | 0.010* | |
| Nationality | Saudi | 493 | 71.3 | 198 | 28.7 | |
| Non-Saudi | 20 | 80.0 | 5 | 20.0 | 0.346 | |
| Marital status | Single | 213 | 70.5 | 89 | 29.5 | |
| Married | 278 | 72.4 | 106 | 27.6 | ||
| Divorced | 20 | 71.4 | 8 | 28.6 | ||
| Widowed | 2 | 100.0 | 0 | 0.0 | 0.781 | |
| Children | No | 278 | 69.2 | 124 | 30.8 | |
| Yes | 235 | 74.8 | 79 | 25.2 | .094 | |
| Monthly income | <7K SAR | 274 | 78.7 | 74 | 21.3 | |
| 7K-15K SAR | 149 | 68.0 | 70 | 32.0 | ||
| 15K-20K SAR | 62 | 64.6 | 34 | 35.4 | ||
| >20K SAR | 28 | 52.8 | 25 | 47.2 | <0.001* | |
| Professional status | Housewife | 123 | 78.3 | 34 | 21.7 | |
| Employed | 230 | 68.0 | 108 | 32.0 | ||
| Businessman/self employed | 13 | 81.3 | 3 | 18.8 | ||
| Student | 128 | 69.9 | 55 | 30.1 | ||
| Retired | 19 | 86.4 | 3 | 13.6 | 0.062 | |
| Educational level | Primary or lower | 4 | 80.0 | 1 | 20.0 | |
| Middle school | 10 | 71.4 | 4 | 28.6 | ||
| Secondary school | 115 | 81.0 | 27 | 19.0 | ||
| University | 328 | 70.8 | 135 | 29.2 | ||
| Post-graduate | 56 | 60.9 | 36 | 39.1 | 0.020* | |
| Health insurance status | None | 345 | 69.8 | 149 | 30.2 | |
| Through employer | 152 | 76.4 | 47 | 23.6 | ||
| Purchased directly | 16 | 69.6 | 7 | 30.4 | 0.219 | |
| Residency region | North | 53 | 70.7 | 22 | 29.3 | |
| South | 48 | 72.7 | 18 | 27.3 | ||
| Center | 162 | 78.3 | 45 | 21.7 | ||
| East | 131 | 70.1 | 56 | 29.9 | ||
| West | 119 | 65.7 | 62 | 34.3 | 0.097 | |
| Hypertension | No | 485 | 72.1 | 188 | 27.9 | |
| Yes | 28 | 65.1 | 15 | 34.9 | 0.327 | |
| Type 2 diabetes | No | 493 | 72.2 | 190 | 27.8 | |
| Yes | 20 | 60.6 | 13 | 39.4 | 0.150 | |
| Thyroid dysfunction | No | 482 | 71.7 | 190 | 28.3 | |
| Yes | 31 | 70.5 | 13 | 29.5 | 0.856 | |
| Dyslipidemia | No | 396 | 72.0 | 154 | 28.0 | |
| Yes | 117 | 70.5 | 49 | 29.5 | 0.704 | |
| Eating disorder | No | 426 | 72.0 | 166 | 28.0 | |
| Yes | 87 | 70.2 | 37 | 29.8 | 0.686 | |
| Asthma | No | 506 | 71.9 | 198 | 28.1 | |
| Yes | 7 | 58.3 | 5 | 41.7 | 0.302 | |
| GIT (ulcer, IBS..) | No | 503 | 71.3 | 202 | 28.7 | |
| Yes | 10 | 90.9 | 1 | 9.1 | 0.153 | |
| Psychiatric history | No | 487 | 72.9 | 181 | 27.1 | |
| Yes | 26 | 54.2 | 22 | 45.8 | 0.005* | |
| Other chronic disease | No | 467 | 71.5 | 186 | 28.5 | |
| Yes | 46 | 73.0 | 17 | 27.0 | 0.801 | |
| Number of comorbidities | None | 294 | 73.9 | 104 | 26.1 | |
| 1 | 129 | 72.1 | 50 | 27.9 | ||
| 2 | 49 | 61.3 | 31 | 38.8 | ||
| 3+ | 41 | 69.5 | 18 | 30.5 | 0.146 | |
| Use of WMMs | Never | 477 | 75.4 | 156 | 24.6 | |
| Ever | 36 | 43.4 | 47 | 56.6 | <0.001> | |
Factors associated with attitudes toward WMMs
Table 7 examines factors associated with attitudes toward WMMs. Notably, none of the sociodemographic or health-related factors showed a statistically significant association with attitudes toward WMMs (p>0.05). However, the use of WMMs did show a significant correlation (p=0.007*), with those who have ever used WMMs exhibiting a more favorable attitude than those who have never used them. It is worth mentioning that females were found to be slightly more likely to have an unfavorable attitude toward WMMs compared to males (84.7% vs 79.9%). Attitudes seemed to be slightly less favorable among those with post-graduate education (90.2% unfavorable) compared to university degree holders (81.9% unfavorable). Participants with an eating disorder had a higher percentage of unfavorable attitudes (87.1%) compared to those without (81.9%). These nuances, while not statistically significant, may still be important to consider in a comprehensive understanding of attitudes toward WMMs.
Table 7. Factors associated with attitude.
WMM, weight management medication; GIT, gastrointestinal tract; IBS, irritable bowel syndrome
| Factor | Level | Unfavorable | Favorable | p-Value | ||
| N | % | N | % | |||
| Gender | Male | 218 | 79.9 | 55 | 20.1 | |
| Female | 375 | 84.7 | 68 | 15.3 | 0.098 | |
| Age | 18-25 | 157 | 79.3 | 41 | 20.7 | |
| 26-35 | 223 | 85.4 | 38 | 14.6 | ||
| 36-45 | 133 | 84.2 | 25 | 15.8 | ||
| 46-50 | 41 | 80.4 | 10 | 19.6 | ||
| Above 50 | 39 | 81.3 | 9 | 18.8 | 0.479 | |
| Nationality | Saudi | 572 | 82.8 | 119 | 17.2 | |
| Non-Saudi | 21 | 84.0 | 4 | 16.0 | 0.874 | |
| Marital status | Single | 247 | 81.8 | 55 | 18.2 | |
| Married | 319 | 83.1 | 65 | 16.9 | ||
| Divorced | 25 | 89.3 | 3 | 10.7 | ||
| Widowed | 2 | 100.0 | 0 | 0.0 | 0.687 | |
| Children | No | 327 | 81.3 | 75 | 18.7 | |
| Yes | 266 | 84.7 | 48 | 15.3 | 0.236 | |
| Monthly income | <7K SAR | 286 | 82.2 | 62 | 17.8 | |
| 7K-15K SAR | 180 | 82.2 | 39 | 17.8 | ||
| 15K-20K SAR | 82 | 85.4 | 14 | 14.6 | ||
| >20K SAR | 45 | 84.9 | 8 | 15.1 | .855 | |
| Professional status | Housewife | 134 | 85.4 | 23 | 14.6 | |
| Employed | 284 | 84.0 | 54 | 16.0 | ||
| Businessman/self employed | 13 | 81.3 | 3 | 18.8 | ||
| Student | 145 | 79.2 | 38 | 20.8 | ||
| Retired | 17 | 77.3 | 5 | 22.7 | 0.524 | |
| Educational level | Primary or lower | 3 | 60.0 | 2 | 40.0 | |
| Middle school | 9 | 64.3 | 5 | 35.7 | ||
| Secondary school | 119 | 83.8 | 23 | 16.2 | ||
| University | 379 | 81.9 | 84 | 18.1 | ||
| Post-graduate | 83 | 90.2 | 9 | 9.8 | 0.058 | |
| Health insurance status | None | 404 | 81.8 | 90 | 18.2 | |
| Through employer | 171 | 85.9 | 28 | 14.1 | ||
| Purchased directly | 18 | 78.3 | 5 | 21.7 | 0.356 | |
| Residency region | North | 62 | 82.7 | 13 | 17.3 | |
| South | 54 | 81.8 | 12 | 18.2 | ||
| Center | 173 | 83.6 | 34 | 16.4 | ||
| East | 157 | 84.0 | 30 | 16.0 | ||
| West | 147 | 81.2 | 34 | 18.8 | 0.960 | |
| Hypertension | No | 557 | 82.8 | 116 | 17.2 | |
| Yes | 36 | 83.7 | 7 | 16.3 | 0.872 | |
| Type 2 diabetes | No | 565 | 82.7 | 118 | 17.3 | |
| Yes | 28 | 84.8 | 5 | 15.2 | 0.752 | |
| Thyroid dysfunction | No | 554 | 82.4 | 118 | 17.6 | |
| Yes | 39 | 88.6 | 5 | 11.4 | 0.291 | |
| Dyslipidemia | No | 453 | 82.4 | 97 | 17.6 | |
| Yes | 140 | 84.3 | 26 | 15.7 | 0.555 | |
| Eating disorder | No | 485 | 81.9 | 107 | 18.1 | |
| Yes | 108 | 87.1 | 16 | 12.9 | 0.165 | |
| Asthma | No | 584 | 83.0 | 120 | 17.0 | |
| Yes | 9 | 75.0 | 3 | 25.0 | 0.469 | |
| GIT (ulcer, IBS, etc.) | No | 584 | 82.8 | 121 | 17.2 | |
| Yes | 9 | 81.8 | 2 | 18.2 | 0.929 | |
| Psychiatric history | No | 553 | 82.8 | 115 | 17.2 | |
| Yes | 40 | 83.3 | 8 | 16.7 | 0.922 | |
| Other chronic disease | No | 542 | 83.0 | 111 | 17.0 | |
| Yes | 51 | 81.0 | 12 | 19.0 | 0.680 | |
| Number of comorbidities | None | 327 | 82.2 | 71 | 17.8 | |
| 1 | 146 | 81.6 | 33 | 18.4 | ||
| 2 | 70 | 87.5 | 10 | 12.5 | ||
| 3+ | 50 | 84.7 | 9 | 15.3 | 0.636 | |
| Use of WMMs | Never | 533 | 84.2 | 100 | 15.8 | |
| Ever | 60 | 72.3 | 23 | 27.7 | 0.007* | |
Discussion
Summary of findings
In light of the escalating obesity epidemic in the Kingdom of Saudi Arabia, worsened by lifestyle changes and the recent COVID-19 pandemic, we conducted this study to assess public understanding and attitudes toward FDA-approved and other commonly used WMMs. Our focus on knowledge and attitudes, alongside the exploration of related socio-demographic, lifestyle, and clinical factors, provides a comprehensive overview of this growing public health concern.
Our study sample encompassed 716 participants, predominantly females 443 (61.9%) aged 26-35 years 261 (36.5%), with a majority holding a university degree 463 (64.7%) and situated in the middle to lower income brackets [219 (30.6%) and 348 (48.6%) respectively]. Their health profiles showed dyslipidemia and eating disorders as the most common chronic conditions, with a majority falling within the normal weight or overweight categories. Weight management strategies were recognized, with diet and exercise being acknowledged as effective by the majority, while there was less consensus on the use of herbal products, pharmaceutical drugs, cognitive and behavioral therapy, and surgery. Knowledge was limited about specific WMMs. Participants generally demonstrated a cautious attitude toward WMMs, with low favorability scores for the statements asserting their effectiveness, safety, and convenience. Nevertheless, it is important to consider these findings in the broader context of understanding knowledge and attitudes related to weight management. Age, income, education, psychiatric history, and past usage of WMMs emerged as significant factors influencing knowledge about weight management. Interestingly, none of the sociodemographic or health-related factors exhibited a statistically significant association with attitudes toward WMMs, except for prior use of these drugs. This study provides crucial insights into the complex interplay of personal, socio-economic, and health factors influencing public knowledge and attitudes concerning weight management strategies.
Knowledge about WMMs
The present study showed variable levels of knowledge about weight management strategies. While diet and exercise were largely acknowledged as effective strategies, pharmaceutical drugs, cognitive and behavioral therapy, and surgery were only recognized by a minority of the participants. Additionally, knowledge about specific WMMs was generally low. The most recognized drugs, i.e. liraglutide (Saxenda) and semaglutide (Ozempic, Wegovy®, Rybelsus®), were reported by about two-thirds of the participants.
Only a few studies have investigated the Saudi’s knowledge and attitude toward WMMs. A 2020 cross-sectional study by Hasan and Ganesh explored the levels of use of orlistat and metformin among 820 female participants. Results showed that 21.3% of the participants used either drug for weight loss, while more than 60% used diet and physical exercise for the same purpose. Of the two medications, orlistat was the most frequently used. The pharmacological method of weight loss was found to be positively correlated to women’s age and marital status. In fact, married Saudi women took more weight loss pills than others. Females between 19 and 25 of age consumed anti-obesity drugs the most [23]. On the other hand, there is more literature available about healthcare professionals’ knowledge and practice in anti-obesity drugs. In 2014, Al-Shammari provided evidence for the under-prescription of anti-obesity drugs in Eastern Saudi Arabia. In this cross-sectional study, 72.3% of physicians said they had never used weight loss medications for the management of obesity. Furthermore, even when required, WMMs were underutilized [24]. Al-Khaldi et al. reported that only 10% of practitioners were knowledgeable of the indications to administer WMMs [25]. Other data suggest that physicians were notified about the unavailability of anti-obesity medications in primary care in 2020 [26].
The findings of this study and the review of previous research highlight significant unfavorability in both the public and professionals toward WMMs use. A key observation is the low recognition and utilization of these drugs, with a clear preference for dietary and physical exercise strategies. The limited use of WMMs in practice, coupled with the prevalent low favorability, calls for more comprehensive education on these interventions. For the public, the focus should be on providing accurate information about the variety of weight management strategies available, including the role and effectiveness of specific medications. For healthcare professionals, the challenge is to promote a better understanding of the indications and usage of these medications. This is of utmost importance given that available literature suggests a degree of under-prescription and under-utilization of WMMs in primary care.
Attitudes towards WMMs
Overall, participants’ attitudes toward WMMs were cautious, demoting misunderstanding or skepticism toward their effectiveness, safety, and convenience. Such uncertainty could lead to lower compliance or outright rejection of these drugs, even when prescribed by healthcare professionals. This could ultimately hinder the successful management of weight-related health issues. Therefore, it is vital to address these misconceptions and enhance patient education about these medications to improve their acceptance and utilization in a clinical setting. Unexpectedly, we observed no correlation of attitudes with knowledge.
Data regarding patients’ attitudes toward WMMs is scarce. However, several studies explored the attitude of prescribers and other healthcare professionals. For instance, Foster et al. study in 2003 explored US physicians' attitudes toward obese patients, as well as their perceptions about the causes and treatment of obesity. Of the 620 respondents from a broad national sample, the consensus was that physical inactivity was recognized as the leading cause of obesity, with other behavioral factors such as overeating and high-fat diets. Regrettably, over half of the physicians held negative stereotypes about obese patients, characterizing them as awkward, unattractive, ugly, and noncompliant. When it came to treatment, obesity intervention was deemed less effective than therapies for most other chronic conditions. However, physicians were realistic about weight loss outcomes, agreeing that a 10% reduction in weight can significantly improve obesity-related health complications. Moreover, most of the respondents were willing to dedicate more time to weight management if they received appropriate compensation [27].
The observed attitudes and perceptions toward obese patients and weight management strategies present significant challenges for effective obesity management. Negative stereotypes held by physicians could potentially impact the patient-doctor relationship and hamper effective communication, leading to suboptimal care. Consequently, addressing these perceptions and attitudes among healthcare professionals is crucial to improve the management of obesity.
On the other hand, despite recognizing obesity as a medically significant issue, a study of French general practitioners revealed a lack of confidence and satisfaction in obesity management, with only 42% considering themselves well-prepared and 51% finding it professionally rewarding. Their unrealistic weight loss goals and low reliance on collaboration with dietitians further complicate obesity management. Moreover, the majority doubted the effectiveness of available drugs. This indicates a need for improved medical education, better collaboration with dietitians, and realistic goal-setting to enhance practices in managing obesity [28].
In Bahrain, a study by Al-Ghawi and Uauy revealed that while physicians acknowledge the severity of the obesity epidemic and express a willingness to take up a significant role in obesity management, their practices and attitudes are hindered by several barriers. Despite their skepticism toward the success rates of weight management, 60% of physicians feel capable of playing a major part in tackling obesity. Their knowledge about weight-loss goals is commendable, and they commonly incorporate obesity identification in chronic disease care. Nevertheless, only 36% of the respondents agree that their weight-management practices are effective. In terms of weight-loss strategies, physicians in Bahrain reportedly utilize a broad range of strategies, excluding pharmacotherapy and surgery. The primary challenges affecting patient care, as identified by the physicians, include time constraints, the absence of specialty clinics, a lack of clear guidelines, and an inadequate number of dietitians. The study concludes that the potential for improved obesity management practices is promising in Bahrain, provided the physicians receive adequate training and the identified obstacles in their working environment are effectively addressed [29].
The studies collectively highlight that attitudes toward obesity and WMMs among both patients and healthcare professionals significantly influence the approach to and efficacy of obesity treatment. Patients' skepticism about WMMs and their safety could hinder the successful management of obesity, underscoring the importance of robust patient education and dispelling misconceptions. However, the attitudes of healthcare professionals are equally critical. Negative stereotypes held by physicians about obese patients can lead to suboptimal care, emphasizing the need to address these perceptions. Across different countries, the confidence and satisfaction of healthcare professionals in managing obesity vary, often hindered by barriers such as time constraints, inadequate support, and unrealistic expectations. These observations suggest that comprehensive strategies involving patient education, improved medical training, and systemic changes in healthcare settings are needed to optimize obesity management practices. These observations underscore a global need for improved training, realistic goal-setting, and better inter-professional collaboration in obesity management. Furthermore, these findings should guide future research and policy initiatives to enhance obesity management on a global scale.
Sociodemographic and health factors
The observed associations highlight that knowledge about WMMs is influenced by various socioeconomic and health-related factors. Notably, younger age (26-35 years), higher income, higher education level, a psychiatric history, and prior use of WMMs are associated with better knowledge about these medications. This suggests that a certain level of exposure and experience, coupled with socioeconomic advantages, might facilitate better understanding and informed perspectives about WMMs.
However, it is intriguing to see that attitudes toward WMMs neither demonstrate a significant association with these same factors, nor with knowledge level. While knowledge is evidently influenced by sociodemographic and health-related conditions, attitudes seem to be more dependent on personal experience with the drugs. This could indicate that attitudes are shaped more by personal encounters and subjective experiences than by knowledge per se.
It is noteworthy that despite the lack of statistical significance, there are certain trends in attitudes worth considering. Females, postgraduates, and those with eating disorders tend to have slightly more unfavorable attitudes toward WMMs. Although these differences are not statistically significant, they might hint at underlying disparities that could become more apparent in larger or more specific population samples.
In essence, while knowledge about WMMs might be improved by elevating socioeconomic status, enhancing education, and increasing exposure to drugs, shifting attitudes may require more personalized interventions. Attitudes could be influenced by experiences, beliefs, cultural norms, or personal health conditions, and thus might not change solely with increased knowledge. This underscores the complexity of managing obesity and the need for holistic, personalized approaches that take into account not just the patient's knowledge, but also their attitudes and experiences.
Limitations
The study’s main limitation stems from its cross-sectional design. The use of a self-administered questionnaire could lead to response bias due to misunderstandings or social desirability influence. While the study investigated various sociodemographic, lifestyle, and clinical factors, other potential determinants of knowledge and attitudes toward WMMs, such as healthcare literacy and access to it, may have been overlooked. Finally, as the study was conducted in Saudi Arabia, cultural factors may limit the generalizability of results to other cultural contexts.
Conclusions
This study provides valuable insights into the understanding and attitudes toward FDA-approved and other commonly used WMMs among the general population in Saudi Arabia. It reveals significant variations and limited knowledge about weight management strategies, specifically WMMs. Furthermore, it highlights the general uncertainty and lack of consensus regarding the effectiveness, safety, and ease of use of these pharmaceutical products. Socioeconomic factors, such as age, income, and education level, as well as psychiatric history and past use of WMMs, have been found to significantly influence knowledge levels. However, these factors, with the exception of prior WMM use, do not significantly affect attitudes toward these drugs.
These findings might shed light on the need for targeted educational initiatives and public health interventions aimed at increasing public knowledge and guiding attitudes about WMMs. As obesity continues to be a global health concern, it is crucial to promote the safe and effective use of these medications while mitigating their potential misuse. The information gathered in this study may serve as a foundational basis for future research and health interventions, ultimately contributing to more informed and effective weight management strategies. Future research could focus on the practices of the Saudi population when using WMMs, their reasons and motivators to use them, and their understanding of potential side effects.
Acknowledgments
We would like to thank all participants and data collectors who made this study possible.
The authors have declared that no competing interests exist.
Human Ethics
Consent was obtained or waived by all participants in this study. Standing Committee for Scientific Research - Jazan University (HAPO-10-Z-001) issued approval REC-44/09/599
Animal Ethics
Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.
References
- 1.The genetics of obesity: from discovery to biology. Loos RJ, Yeo GS. Nat Rev Genet. 2022;23:120–133. doi: 10.1038/s41576-021-00414-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Obesity: an emerging problem in Saudi Arabia. Analysis of data from the National Nutrition Survey. Al-Othaimeen AI, Al-Nozha M, Osman AK. https://pubmed.ncbi.nlm.nih.gov/17684864/ East Mediterr Health J. 2007;13:441–448. [PubMed] [Google Scholar]
- 3.Prevalence of overweight and obesity based on the body mass index; a cross-sectional study in Alkharj, Saudi Arabia. Al-Ghamdi S, Shubair MM, Aldiab A, et al. Lipids Health Dis. 2018;17:1–8. doi: 10.1186/s12944-018-0778-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.A review of prevalence of obesity in Saudi Arabia. Alqarni SS. J Obes Eat Disord. 2016;2:1–6. [Google Scholar]
- 5.Prevalence and predictors of obesity and overweight among adults visiting primary care settings in the Southwestern Region, Saudi Arabia. Al-Qahtani AM. Biomed Res Int. 2019;2019:1–5. doi: 10.1155/2019/8073057. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Physical inactivity in Saudi Arabia revisited: a systematic review of inactivity prevalence and perceived barriers to active living. Al-Hazzaa HM. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257875/ Int J Health Sci (Qassim) 2018;12:50–64. [PMC free article] [PubMed] [Google Scholar]
- 7.Obesity and overweight in a major family practice center, central region, Saudi Arabia. Al-Haqwi A, Al-Nasir M, Ahmad N, et al. Saudi J Obesity. 2015;3:12–17. [Google Scholar]
- 8.Changes in nutritional habits and lifestyles during the COVID-19 lockdown period in Saudi Arabia: a cross-sectional study. Alqurashi RM. Curr Res Nutr Food Sci. 2021;9:934–944. [Google Scholar]
- 9.Complications of obesity. Kinlen D, Cody D, O'Shea D. QJM. 2018;111:437–443. doi: 10.1093/qjmed/hcx152. [DOI] [PubMed] [Google Scholar]
- 10.The Saudi clinical practice guideline for the management of overweight and obesity in adults. Alfadda AA, Al-Dhwayan MM, Alharbi AA, et al. Saudi Med J. 2016;37:1151–1162. doi: 10.15537/smj.2016.10.14353. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Saudi population’s adherence to the healthy food palm: a cross-sectional study. Halawani R, Jaceldo-Siegl K, Heskey C, et al. FASEB J. 2019;33:755–764. [Google Scholar]
- 12.Clinical practice guideline for the management of overweight and obesity in adults in Saudi Arabia. Alshaikh A, Aljedai A, Alfadda A, et al. Int J Clin Med. 2022;13:590–649. [Google Scholar]
- 13.Anti-obesity therapy: from rainbow pills to polyagonists. Müller TD, Clemmensen C, Finan B, et al. Pharmacol Rev. 2018;70:712–746. doi: 10.1124/pr.117.014803. [DOI] [PubMed] [Google Scholar]
- 14.Anti-obesity drugs: a review about their effects and safety. Kang JG, Park CY. Diabetes Metab J. 2012;36:13–25. doi: 10.4093/dmj.2012.36.1.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Long-term efficacy and safety of anti-obesity treatment: where do we stand? Tak YJ, Lee SY. Curr Obes Rep. 2021;10:14–30. doi: 10.1007/s13679-020-00422-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.U.S. Food & Drug Administration. Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin) 2020. https://www.fda.gov/drugs/drug-safety-and-availability/safety-clinical-trial-shows-possible-increased-risk-cancer-weight-loss-medicine-belviq-belviq-xr https://www.fda.gov/drugs/drug-safety-and-availability/safety-clinical-trial-shows-possible-increased-risk-cancer-weight-loss-medicine-belviq-belviq-xr
- 17.Lorcaserin: a selective serotonin receptor (5-HT2C) agonist for the treatment of obesity. Kataria BC. https://www.ijbcp.com/index.php/ijbcp/article/view/1398 IJBCP. 2012;1:45–47. [Google Scholar]
- 18.FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market. https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market 2020;3:5. [Google Scholar]
- 19.Martin JL, Pazienza R. Taylor & Francis Group. 9781315175799. United Kingdom: Taylor & Francis Group; 2018. Nonmedical Use of Prescription Drugs by College Students: Emerging Trends and Challenges. Promoting Behavioral Health and Reducing Risk Among College Students; p. 14. [Google Scholar]
- 20.Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawal. Blanck HM, Khan LK, Serdula MK. Prev Med. 2004;39:1243–1248. doi: 10.1016/j.ypmed.2004.04.040. [DOI] [PubMed] [Google Scholar]
- 21.Dispensing practices for weight management products in Eastern Saudi Arabia: a survey of community pharmacists. Elrggal ME, Alamer SI, Alkahtani SA, et al. Int J Environ Res Public Health. 2021;18:13146. doi: 10.3390/ijerph182413146. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Community pharmacy and the extended community pharmacist practice roles: the UAE experiences. Sadek MM, Elnour AA, Al Kalbani NM, et al. Saudi Pharm J. 2016;24:563–570. doi: 10.1016/j.jsps.2015.03.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Weight lowering medications to alter morphological indices: a cross-sectional study among Saudi females. Hasan T, Ganesh K. https://www.iomcworld.org/articles/weight-lowering-medications-to-alter-morphological-indices-a-crosssectional-study-among-saudi-females.pdf J Biol Today's World. 2020;9:1–8. [Google Scholar]
- 24.Attitudes and practices of primary care physicians in the management of overweight and obesity in eastern Saudi Arabia. Al-Shammari YF. Int J Health Sci (Qassim) 2014;8:151–158. doi: 10.12816/0006081. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Knowledge, attitude and practice of primary health care physicians in Aseer region regarding obesity. Al-Khaldi YM, Melha WS, Al-Shahrani AM, et al. Saudi J Obesity. 2014;2:54–58. [Google Scholar]
- 26.Physicians’ knowledge, feelings, attitudes, and practices toward obesity at family medicine setting in Riyadh, Saudi Arabia. Noor M, Horaib Y, Almusallam N, et al. IJMDC. 2020;4:130–136. [Google Scholar]
- 27.Primary care physicians' attitudes about obesity and its treatment. Foster GD, Wadden TA, Makris AP, et al. Obes Res. 2003;11:1168–1177. doi: 10.1038/oby.2003.161. [DOI] [PubMed] [Google Scholar]
- 28.Obesity management: attitudes and practices of French general practitioners in a region of France. Thuan JF, Avignon A. https://www.nature.com/articles/0803016. Int J Obes. 2005;29:1100–1106. doi: 10.1038/sj.ijo.0803016. [DOI] [PubMed] [Google Scholar]
- 29.Study of the knowledge, attitudes and practices of physicians towards obesity management in primary health care in Bahrain. Al-Ghawi A, Uauy R. Public Health Nutr. 2009;12:1791–1798. doi: 10.1017/S1368980008004564. [DOI] [PubMed] [Google Scholar]